拉贝珠单抗
外观
单克隆抗体 | |
---|---|
种类 | 完整抗体 |
目標 | 癌胚抗原 |
臨床資料 | |
ATC碼 |
|
识别信息 | |
CAS号 | 219649-07-7 ![]() |
ChemSpider |
|
UNII | |
KEGG |
拉贝珠单抗(INN:labetuzumab;商品名CEA-CIDE)是一种人源化IgG1单克隆抗体,用于治疗结直肠癌。[1]它选择性地结合CEACAM5。[2]
该药物还被用在患有转移的甲状腺髓样癌患者中进行了测试。[3]
该药物由Immunomedics开发。
参考资料
[编辑]- ^ International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab (PDF). WHO Drug Information. 2002, 16 (1): 95.
- ^ labetuzumab-SN-38 immunoconjugate IMMU-130. National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services.
- ^ Stein, Rhona; Goldenberg, David M. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Molecular Cancer Therapeutics. 2004-12, 3 (12). ISSN 1535-7163. PMID 15634649.
|